Vertex Pharmaceuticals VRTX Other — Product revenues, net
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's other — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's other — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported other — product revenues, net of $261M in Q1 2026.
- How has Vertex Pharmaceuticals's other — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's other — product revenues, net decreased by 6.8% year-over-year, from $280.1M to $261M.
- What is the long-term trend for Vertex Pharmaceuticals's other — product revenues, net?
- Over 2 years (2022 to 2024), Vertex Pharmaceuticals's other — product revenues, net has grown at a 29.5% compound annual growth rate (CAGR), from $525.9M to $881.3M.
- What does other — product revenues, net mean?
- Net revenue earned from product sales in international markets excluding the primary domestic and major European regions.
- How do you interpret other — product revenues, net?
- An increase indicates successful market penetration and growing demand in secondary international territories, while a decrease may signal competitive pressure or regulatory hurdles in those regions.
- How does other — product revenues, net compare across companies?
- Peers typically report this as 'Rest of World' revenue, which is often compared against total international revenue to gauge geographic diversification.